-
Talc lawyer says J&J's multibillion-dollar stock woes make settling look like a better deal
fiercepharma
December 25, 2018
What's bad for Johnson & Johnson shares is good for the trial lawyer leading the charge in the talc liability litigation—or so the lawyer says, as J&J scrambles to contain the damage from a bombshell Reuters report Friday.
-
Talc lawyer says J&J's multibillion-dollar stock woes make settling look like a better deal
pharmatimes
December 20, 2018
What's bad for Johnson & Johnson shares is good for the trial lawyer leading the charge in the talc liability litigation—or so the lawyer says, as J&J scrambles to contain the damage from a bombshell Reuters report Friday.
-
Innovation challenges multiply: Will pharma seeking tech entrepreneurs drain the brain pool?
fiercepharma
December 20, 2018
Innovation challenges had already shaped up as a trend last year, but this trend really has legs. Not only did even more drugmakers launch their own challenges this year, but those already involved added more.
-
Johnson & Johnson’s Tremfya tops Novartis blockbuster Cosentyx in head-to-head psoriasis showdown
fiercepharma
December 14, 2018
Johnson & Johnson’s Tremfya may have made its debut after key rivals, but it made waves Wednesday in the next-gen psoriasis field with Cosentyx-topping head-to-head data.
-
Vect-Horus Announces Agreement With Johnson & Johnson Innovation
pharmafocusasia
December 13, 2018
Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
-
BiomX Enters Collaboration with Johnson & Johnson Innovation for Discovery of Microbiome-based Biomarkers for IBD
pharmafocusasia
December 13, 2018
BiomX Ltd., a microbiome company developing customized phage therapies, today announced that it has entered into a collaboration with Janssen Research & Development...
-
Vect-Horus Announces Agreement With Johnson & Johnson Innovation
pharmafocusasia
December 12, 2018
Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson......
-
Johnson & Johnson shares swoon as pharma giant loses yet another fight to protect Zytiga sales
fiercepharma
December 10, 2018
Johnson & Johnson lost its latest effort to fend off Zytiga generics in court, sending investors reeling at the prospect of losing blockbuster sales. But the pharma giant says it’s now planning
-
Johnson & Johnson pays $300m to develop cusatuzumab
pharmatimes
December 06, 2018
Johnson & Johnson's Janssen has entered into an agreement potentially worth up to $1.6 billion to develop and market Argenx' cusatuzumab for a number of cancers, including haematological malignancies.
-
Johnson & Johnson pays $300 million upfront under deal to develop argenx's cancer drug cusatuzumab
firstwordpharma
December 03, 2018
Johnson & Johnson's Janssen Pharmaceutical unit entered an agreement potentially worth up to $1.6 billion to develop and market argenx's cusatuzumab in a number of cancers, including haematological malignancies, the companies announced Monday.